Scarica l'app Stockscreener
18.81
3.54%
-0.69
Dopo l'orario di chiusura:
18.47
-0.34
-1.81%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.50
Aprire:
$19.52
Volume 24 ore:
840.76K
Relative Volume:
0.57
Capitalizzazione di mercato:
$164.89M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-1.6705
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
-16.55%
1M Prestazione:
-30.64%
6M Prestazione:
+18.60%
1 anno Prestazione:
+18.30%
Intervallo 1D:
$18.78
$20.69
Intervallo di 1 settimana:
$18.78
$22.38
Portata 52W:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Confronta TNXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
18.81 | 175.41M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Sentiment analysis tools applied to Tonix Pharmaceuticals Holding Corp.Bull Run & Accurate Trade Setup Notifications - newser.com
Tonix Pharmaceuticals Holding Corp. stock retracement – recovery analysisEarnings Growth Report & Pattern Based Trade Signal System - newser.com
How to recover losses in Tonix Pharmaceuticals Holding Corp. stockWeekly Volume Report & Short-Term High Return Strategies - newser.com
Using portfolio simulators with Tonix Pharmaceuticals Holding Corp. includedQuarterly Profit Review & Low Drawdown Momentum Trade Ideas - newser.com
Automated trading signals detected on Tonix Pharmaceuticals Holding Corp.2025 EndofYear Setup & Risk Managed Investment Signals - newser.com
Tonix CEO presents anti-CD154 antibody research at Japan transplant congress - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Highlights Advancements in Transpla - GuruFocus
How Tonix Pharmaceuticals Holding Corp. stock performs after earningsJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Tonix Pharmaceuticals Presented an Update on Fc-modified - GlobeNewswire
Phase 1 safety & biomarker data lead Tonix's TNX-1500 toward Phase 2 for kidney transplant prevention - Stock Titan
Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
Backtesting results for Tonix Pharmaceuticals Holding Corp. trading strategiesWeekly Market Outlook & Daily Profit Focused Screening - newser.com
Analyzing Tonix Pharmaceuticals Holding Corp. with risk reward ratio chartsJuly 2025 Breakouts & Smart Money Movement Tracker - newser.com
Tonix Pharmaceuticals Holding Corp. stock daily chart insightsJuly 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat
Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK - Barchart.com
Fibromyalgia Market Expected to Gain Momentum Through 2034, - openPR.com
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 - The Manila Times
Single‑Dose TNX-801 Mpox Vaccine: Tonix to Present Safety & Durability Data at World Vaccine Congress Europe - Stock Titan
Detecting price anomalies in Tonix Pharmaceuticals Holding Corp. with AI2025 Sector Review & Real-Time Buy Signal Notifications - newser.com
What analysts say about Tonix Pharmaceuticals Holding Corp stockResistance Breakout Alerts & Affordable Growth Strategies - earlytimes.in
Tonix Pharmaceuticals (TNXP) Plans New Phase 2 Trials for Key Tr - GuruFocus
Tonix Pharma Plans Phase 2 Trial for 2026 - TipRanks
Tonix to advance cyclobenzaprine into phase 2 for depression - Seeking Alpha
Is Tonix Pharmaceuticals Holding Corp. trending in predictive chart models2025 Investor Takeaways & Daily Price Action Insights - newser.com
Custom watchlist performance reports with Tonix Pharmaceuticals Holding Corp.2025 Valuation Update & Safe Capital Growth Tips - newser.com
What data driven models say about Tonix Pharmaceuticals Holding Corp.’s futureWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Tonix Pharmaceuticals advances TNX-2900 into Phase 2 trial for Prader-Willi Syndrome - Proactive financial news
Tonix Pharma Appoints New Head of Market Access - MSN
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access - Sahm
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access By Investing.com - Investing.com Nigeria
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome to Phase 2 Clinical Trial - citybuzz
Tonix Pharmaceuticals Further Strengthens Commercial - GlobeNewswire
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access - citybiz
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain? - PharmaVoice
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
| LEDERMAN SETH | Chief Executive Officer |
May 15 '25 |
Buy |
21.55 |
4,000 |
86,200 |
4,005 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):